This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
insurance-premium: Archive
Is Skyward Stock a Buy After the Pullback and Higher Leverage?
by Kaibalya Pravo Dey
SKWD's pullback raises questions as leverage climbs post-Apollo, but strong earnings, growth outlook and improving underwriting keep the long-term case intact.
ALLNegative Net Change HRTGNegative Net Change SKWDNegative Net Change
finance insurance insurance-premium
How Skyward's Niche Playbook Shields it From Pricing Pressure & Cycles
by Kaibalya Pravo Dey
SKWD leans on niche underwriting and new fee income streams to defend pricing power and sustain growth through shifting insurance cycles.
ALLNegative Net Change HCINegative Net Change HRTGNegative Net Change SKWDNegative Net Change
finance insurance insurance-premium
UnitedHealth vs. Humana: Which Healthcare Stock Has More Upside Now?
by Rajshree Sipani
UNH's scale and diversified model are likely to offer stronger upside than HUM as rising medical costs test managed care margins.
UNHNegative Net Change HUMNegative Net Change
artificial-intelligence healthcare hmo insurance insurance-premium medical smart-health
UnitedHealth's Q4 Beat Can't Stop the Slide: Should You Let Go Now?
by Kaibalya Pravo Dey
UNH beats Q4 EPS, but the stock plunges 21.5% as medical costs spiked, margins sank, and Medicare reimbursement risk clouded its outlook.
UNHNegative Net Change MOHNegative Net Change CNCNegative Net Change
earnings-report earnings-surprise healthcare hmo insurance insurance-premium medical
UNH vs. ELV: Which Managed Care Stock Has the Edge Today?
by Rajshree Sipani
Elevance Health is edging past UnitedHealth as Carelon's growth, strategic exits and a cheaper valuation shape a stronger near-term setup.
UNHNegative Net Change ELVNegative Net Change
artificial-intelligence dental finance healthcare hospitals insurance insurance-premium medical smart-health
Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?
by Kaibalya Pravo Dey
UNH trades below its five-year median P/E as it navigates margin pressure, membership declines and strategic divestments.
UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change
healthcare hmo insurance insurance-premium medical
UnitedHealth's Q3 Beat Isn't Stopping the Bleed: Hold or Fold Now?
by Kaibalya Pravo Dey
UNH's Q3 earnings beat couldn't stop a 9.6% stock slide as rising medical costs and margin strain test investor patience.
UNHNegative Net Change MOHNegative Net Change CNCNegative Net Change
earnings-surprise hmo insurance insurance-premium medical
UnitedHealth Recovers Its Rhythm Before Q3 Earnings: Time to Buy?
by Kaibalya Pravo Dey
UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.
UNHNegative Net Change HUMNegative Net Change MOHNegative Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical
UNH or ELV: Which Healthcare Titan Will Regain Investor Trust First?
by Kaibalya Pravo Dey
UnitedHealth and Elevance battle rising costs, but scale, Optum, and Buffett's backing give UNH the edge in restoring investor trust.
UNHNegative Net Change ELVNegative Net Change
hmo insurance insurance-premium medical
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
by Kaibalya Pravo Dey
ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.
UNHNegative Net Change CNCNegative Net Change ELVNegative Net Change
earnings-outlook healthcare hmo insurance insurance-premium medical